DARA BioSciences announced the signing of an agreement with Alamo Pharma Services, a subsidiary of Mission Pharmacal, for a twenty person national sales team in the U.S. oncology market. Pursuant to the agreement and a shared sales force agreement with Mission, the Alamo sales team in addition to promoting Dara's products Soltamox, Gelclair and Bionect will also carry three Mission Pharmacal products: Ferralet 90, BINOSTO, and Aquoral. The agreements with Alamo and Mission expand DARA's presence in oncology supportive care to address ongoing areas of unmet medical need. DARA implemented a refined commercial strategy at the end of Q2, realigning the original sales force of five representatives to smaller territories, thereby increasing sales call frequency to targeted high volume customers. The outcome of this refinement was a significant increase in product sales in Q3 compared with the previous quarter. Increasing the field sales organization, through its partnership with Alamo Pharma Services, is expected to continue to drive this product momentum and provide the necessary scope and coverage of high prescribing oncologists maximizing the potential of DARA's product portfolio. The combined product and commercial expansion are both integral parts of DARA's long-term strategy to become the leader in the field of oncology supportive care. The Company expects to have the sales force trained and in the field by January 1, 2014.